Regulatory mechanism of xiebai san on LPS-induced acute lung injury in juvenile rats

doi:10.11958/20252076

Abstract

Abstract:

Objective To elucidate the regulatory mechanism of xiebai san (XBS) and its combination with azithromycin (AZM) on LPS-induced acute lung injury (ALI) in juvenile rats. Methods Thirty rats were divided into the control group, the model group, the AZM group, the XBS group and the XBS combined with AZM (combined) group according to body weight by stratified random method, with 6 rats in each group. In addition to the control group, the other groups were treated with aerosol inhalation of LPS to establish the ALI model of young rats. Levels of superoxide dismutase (SOD), malondialdehyde (MDA) and catalase (CAT) in lung tissue were detected using biochemical kits. Serum interleukin (IL-6, IL-10 and IL-13) and nuclear factor-κB (NF-κB) were measured by enzyme-linked immunosorbent assay. Transcriptomic analysis was performed to identify differentially expressed genes (DEGs) in lung tissue, followed by enrichment analysis. Immunohistochemistry was used to assess cyclooxygenase-2 (COX-2) and tumor necrosis factor-α (TNF-α) expression in lung tissue. Results Compared with the control group, the activities of SOD and CAT in lung tissue of rats decreased in the model group, and the content of MDA increased (P < 0.05). Serum levels of IL-6, IL-10, IL-13 and NF-κB all increased (P < 0.05). Compared with the model group, SOD and CAT activities in lung tissue significantly increased in the AZM group and the combined group（P<0.05), while SOD activity increased and MDA content decreased in the XBS group. Serum inflammatory factors IL-6, IL-10 and IL-13 levels were significantly reduced in the AZM group, the XBS group and the combined group, with NF-κB levels also decreasing in the XBS group（P<0.05). Transcriptomic analysis revealed that XBS and its combination with AZM alleviated ALI by modulating the IL-17 signaling pathway. Immunohistochemistry indicated significantly reduced COX-2 and TNF-α expression in the AZM group, the XBS group and the combined group compared to those of the model group. Conclusion XBS and its combination with azithromycin may ameliorate ALI in juvenile rats by regulating the IL-17 signaling pathway, oxidative stress, inflammatory responses and lung gene expression.

Key words: acute lung injury, Xie Bai San, transcriptome, azithromycin

CLC Number:

R285

Figures/Tables 8

References 21

[1]	钱乙宋. 小儿药证直诀[M]. 北京: 人民卫生出版社, 2023:62.
	QIAN Y S. Pediatric medicine certificate[M]. Beijing: People's Health Publishing House, 2023:62.
[2]	李玉丽, 易腾达, 谭志强, 等. 经典名方泻白散的源流及古今应用考究[J]. 中国实验方剂学杂志, 2021, 27(4):168-174.
	LI Y L, YI T D, TAN Z Q, et al. The origin and application of Xiebai Powder[J]. Chinese Journal of Experimental Formulaology, 2021, 27(4):168-174. doi:10.13422/j.cnki.syfjx.20202328.
[3]	LIN P, GAO R, FANG Z, et al. Precise nanodrug delivery systems with cell-specific targeting for ALI/ARDS treatment[J]. Int J Pharm, 2023, 644:123321. doi:10.1016/j.ijpharm.2023.123321.
[4]	XU Z, SHI L, WANG Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome[J]. Lancet Respir Med, 2020, 8(4):420-422. doi:10.1016/S2213-2600(20)30076-X.
[5]	HE Y, YANG F, YANG L, et al. Mechanics-activated fibroblasts promote pulmonary group 2 innate lymphoid cell plasticity propelling silicosis progression[J]. Nat Commun, 2024, 15(1):9770. doi:10.1038/s41467-024-54174-5.
[6]	FU L, ZHU P, QI S, et al. MicroRNA-92a antagonism attenuates lipopolysaccharide (LPS)-induced pulmonary inflammation and injury in mice through suppressing the PTEN/AKT/NF-κB signaling pathway[J]. Biomed Pharmacother, 2018, 107:703-711. doi:10.1016/j.biopha.2018.08.040.
[7]	YANG H H, JIANG H L, TAO J H, et al. Mitochondrial citrate accumulation drives alveolar epithelial cell necroptosis in lipopolysaccharide-induced acute lung injury[J]. Exp Mol Med, 2022, 54(11):2077-2091. doi:10.1038/s12276-022-00889-8.
[8]	FU C, DAI X, YANG Y, et al. Dexmedetomidine attenuates lipopolysaccharide-induced acute lung injury by inhibiting oxidative stress,mitochondrial dysfunction and apoptosis in rats[J]. Mol Med Rep, 2017, 15(1):131-138. doi:10.3892/mmr.2016.6012.
[9]	姚素媛, 张庆玲, 王坤然, 等. 泻白散对脂多糖诱导的肺损伤幼龄大鼠炎症及肠道微生态的影响[J]. 中药新药与临床药理, 2025, 36(10):1658-1669.
	YAO S Y, ZHANG Q L, WANG K R, et al. Effects of xiebai san on inflammation and gut microbiota in lipopolysaccharide-induced lung injury in juvenile rats[J]. Traditional Chinese Drug Research & Clinical Pharmacology, 2025, 36(10):1658-1669. doi:10.19378/j.issn.1003-9783.2025.10.005.
[10]	LIU H, BAI C, XIAN F, et al. A high-calorie diet aggravates LPS-induced pneumonia by disturbing the gut microbiota and Th17/Treg balance[J]. J Leukoc Biol, 2022, 112(1):127-141. doi:10.1002/JLB.3MA0322-458RR.
[11]	WU Y, ZHANG Y, TANG X, et al. Synergistic anti-oxidant and anti-inflammatory effects of ceria/resatorvid co-decorated nanoparticles for acute lung injury therapy[J]. J Nanobiotechnology, 2023, 21(1):502. doi:10.1186/s12951-023-02237-y.
[12]	VYSAKH A, JAYESH K, JISHA N, et al. Rotula aquatica lour. mitigates oxidative stress and inflammation in acute pyelonephritic rats[J]. Arch Physiol Biochem, 2022, 128(1):92-100. doi:10.1080/13813455.2019.1665073.
[13]	XING H, BAI X, PEI X, et al. Synergistic anti-oxidative/anti-inflammatory treatment for acute lung injury with selenium based chlorogenic acid nanoparticles through modulating Mapk8ip1/MAPK and Itga2b/PI3k-AKT axis[J]. J Nanobiotechnology, 2025, 23(1):37. doi:10.1186/s12951-025-03114-6.
[14]	SHEU J J, LEE F Y, YUEN C M, et al. Combined therapy with shock wave and autologous bone marrow-derived mesenchymal stem cells alleviates left ventricular dysfunction and remodeling through inhibiting inflammatory stimuli,oxidative stress & enhancing angiogenesis in a swine myocardial infarction model[J]. Int J Cardiol, 2015, 193:69-83. doi:10.1016/j.ijcard.2015.03.044.
[15]	YANG W, HE R, QU H, et al. FXYD3 enhances IL-17A signaling to promote psoriasis by competitively binding TRAF3 in keratinocytes[J]. Cell Mol Immunol, 2023, 20(3):292-304. doi:10.1038/s41423-023-00973-7.
[16]	ZHENG Y, MOU Z, TAN S, et al. IL-17A enhances the inflammatory response of glaucoma through Act1/TRAF6/NF-κB pathway[J]. Neurochem Int, 2024, 178:105787. doi:10.1016/j.neuint.2024.105787.
[17]	WU S, HUANG D, SU X, et al. The prostaglandin synthases,COX-2 and L-PGDS,mediate prostate hyperplasia induced by low-dose bisphenol A[J]. Sci Rep, 2020, 10(1):13108. doi:10.1038/s41598-020-69809-y.
[18]	LI W, CHEN P, ZHAO Y, et al. Human IL-17 and TNF-α additively or synergistically regulate the expression of proinflammatory genes,coagulation-related genes,and tight junction genes in porcine aortic endothelial cells[J]. Front Immunol, 2022, 13:857311. doi:10.3389/fimmu.2022.857311.
[19]	RUIZ DE MORALES J M G, PUIG L, DAUDÉN E, et al. Critical role of interleukin (IL)-17 in inflammatory and immune disorders:An updated review of the evidence focusing in controversies[J]. Autoimmun Rev, 2020, 19(1):102429. doi:10.1016/j.autrev.2019.102429.
[20]	DENG C, LI S, LIU Y, et al. Split-Cas9-based targeted gene editing and nanobody-mediated proteolysis-targeting chimeras optogenetically coordinated regulation of Survivin to control the fate of cancer cells[J]. Clin Transl Med, 2023, 13(8):e1382. doi:10.1002/ctm2.1382.
[21]	COLOMBEL J F, UNGARO R C, SANDS B E, et al. Vedolizumab,adalimumab,and methotrexate combination therapy in crohn's disease(EXPLORER)[J]. Clin Gastroenterol Hepatol, 2024, 22(7):1487-1496.e12. doi:10.1016/j.cgh.2023.09.010.

组别	SOD/ （U/mgprot）	MDA/ （μmol/gprot）	CAT/ （U/mgprot）
Control组	47.04±4.73	0.74±0.12	22.93±1.72
Model组	37.96±6.69^a	1.04±0.13^a	18.60±1.43^a
AZM组	45.98±7.69^b	0.84±0.20	21.45±4.23^b
XBS组	47.31±7.77^b	0.45±0.12^abc	15.34±2.22^ac
Combined组	44.35±2.81^b	1.27±0.26^bcd	24.76±2.85^bd
F	3.933^＊	18.370^＊	11.514^＊

组别	SOD/ （U/mgprot）	MDA/ （μmol/gprot）	CAT/ （U/mgprot）
Control组	47.04±4.73	0.74±0.12	22.93±1.72
Model组	37.96±6.69^a	1.04±0.13^a	18.60±1.43^a
AZM组	45.98±7.69^b	0.84±0.20	21.45±4.23^b
XBS组	47.31±7.77^b	0.45±0.12^abc	15.34±2.22^ac
Combined组	44.35±2.81^b	1.27±0.26^bcd	24.76±2.85^bd
F	3.933^＊	18.370^＊	11.514^＊

组别	IL-6	IL-10	IL-13	NF-κB
Control组	91.76±7.81	68.71±13.08	30.81±1.82	527.25±56.14
Model组	107.90±3.95^a	105.38±15.73^a	37.42±1.16^a	649.71±74.51^a
AZM组	93.56±6.80^b	84.13±3.68^b	33.17±2.12^b	584.86±28.43
XBS组	93.13±8.51^b	84.65±10.05^b	33.03±1.69^b	554.06±27.88^b
Combined组	94.59±5.40^b	83.08±12.41^b	32.31±1.34^b	608.04±36.14^ad
F	5.864^＊	7.474^＊	13.100^＊	5.828^＊

组别	IL-6	IL-10	IL-13	NF-κB
Control组	91.76±7.81	68.71±13.08	30.81±1.82	527.25±56.14
Model组	107.90±3.95^a	105.38±15.73^a	37.42±1.16^a	649.71±74.51^a
AZM组	93.56±6.80^b	84.13±3.68^b	33.17±2.12^b	584.86±28.43
XBS组	93.13±8.51^b	84.65±10.05^b	33.03±1.69^b	554.06±27.88^b
Combined组	94.59±5.40^b	83.08±12.41^b	32.31±1.34^b	608.04±36.14^ad
F	5.864^＊	7.474^＊	13.100^＊	5.828^＊

组别	COX-2/（ng/L）	TNF-α/（ng/L）
Control组	17.38±0.20	16.42±0.11
Model组	27.50±0.58^a	26.34±0.45^a
AZM组	22.25±0.06^ab	18.67±0.05
XBS组	23.72±0.36^abc	23.72±0.36^a
Combined组	19.32±0.23^abcd	17.30±0.03^b
F	397.069^＊	781.689^＊